the evaluation of the anti-histone deacetylase, antibacterial, antioxidant and cytotoxic activities of synthetic n,n´-ethylenebis (α methylsalicylideneiminate) schiff base derivatives

Recently, schiff base complexes as synthetic antioxidants are widely used instead of natural antioxidants because they are effective and cheaper. in this study, a series of α,ά-me2-salen, (n,n´-ethylenebis(α methylsalicylideneiminate)) schiff base derivatives have been investigated for their anti-histone deacetylase (hdac), anticancer, antibacterial, and antioxidant activities. for anti-hdac studies, autodock 4.1 and molecular dynamics (md) simulations have been conducted against these combinations. cytotoxic test, the ferric reducing ability of plasma (frap), 2,2-diphenyl-1-picrylhydrazyl (dpph), and (2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) abts assays and agar diffusion method have been applied to investigate anticancer, antioxidant and antibacterial activities, respectively. based on the results, the best docking was obtained for α,ά-me2-salen against hdac. also, md calculation results demonstrated that the α,ά-me2-salen is a more effective compound for hdac inhibiting than saha as a known enzyme inhibitor. however, α,ά-me2-salen, and its derivatives didn’t display antibacterial activity against any of the microorganisms. cytotoxic activity analysis toward mcf 7 cell line was apparent that α,ά-me2-salen and its ni (ii), co (ii), and cu (ii) derivatives manifested high cytotoxic activity with ic50 5, 2, 2, and 3 µg/ml, respectively. the antioxidant results revealed excellent radical scavenging activities of all these compounds against dpph, abts, and frap radicals. the antioxidant activity by dpph, showed mn(ii) complex (ic50 = 0.13 ± 0.50 mg/ml) was the most active. while, α,ά-me2-salen (ic50 =0.05±0.003 mg/ml) and its ni(ii) derivative (ic50 =0.049 mg/ml) exhibited the highest abts scavenging activity. according to the results, all compounds show acceptable anticancer and antioxidant activity and can be used as drug candidates after further investigations.